Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study.
Blood Adv
; 6(5): 1444-1453, 2022 03 08.
Article
in En
| MEDLINE
| ID: mdl-34581764
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Primary Myelofibrosis
/
Graft vs Host Disease
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Blood Adv
Year:
2022
Document type:
Article